The latest ovarian cancer news and blogs from Target Ovarian Cancer, including fundraising, campaigns, research and support news, and blogs from people affected by ovarian cancer. Scroll down for our events listings, including support and fundraising events.

Information is correct at the time of publication, please note information in historical news stories around drug availability or statistics may not still be relevant.

News
researcher looking at agar plates
Friday 11 October 2019
The National Institute for Health and Care Excellence (NICE) today announced a third ovarian cancer drug, PARP inhibitor rucaparib (Rubraca®), is now available to women with ovarian cancer from after a second round of chemotherapy. It will be available both for women who have a BRCA1 or BRCA2...
News
Donate
Friday 27 September 2019
News from the European Society of Medical Oncology (ESMO) conference means more women could be able to access innovative treatments earlier. Three announcements on the benefits of a new generation of ovarian cancer drugs, PARP inhibitors, were made over the weekend at the research conference in...
News
Thursday 25 July 2019
The National Institute for Health and Care Excellence (NICE) has for the first time approved a breakthrough ovarian cancer drug from the first round of treatment. Olaparib (Lynparza®) is one of a new generation of drugs known as PARP inhibitors, which work by stopping cancer cells from repairing...
News
Friday 7 June 2019
Target Ovarian Cancer’s Chief Executive Annwen Jones has been awarded an OBE in this year’s Queen’s birthday honours. Annwen established Target Ovarian Cancer alongside Joanna Barker MBE and Frances Reid in 2008. Since that time, the charity has grown rapidly and is now at the forefront of work...

Pages